Why the study?
Do direct oral anticoagulants (DOACs) prevent postoperative venous thromboembolism as effectively and safely as low-molecular-weight heparin (LMWH) in adult patients undergoing cancer-related surgeries?
Do direct oral anticoagulants (DOACs) prevent postoperative venous thromboembolism as effectively and safely as low-molecular-weight heparin (LMWH) in adult patients undergoing cancer-related surgeries?
Answers are grounded in this paper and cite their sources.
DOACs represent a safe and efficacious oral alternative to LMWH for post-operative thromboprophylaxis in cancer patients, demonstrating comparable VTE prevention and bleeding risk profiles.
DOACs appear non-inferior to LMWH for post-operative thromboprophylaxis in patients undergoing cancer-related surgeries, with comparable safety. The superior VTE prevention in urological cancer surgeries and Apixaban's favorable safety profile warrant further investigation. Moreover, additional research is necessary to clarify the roles of specific DOACs and optimal prophylaxis strategies across various cancer types and surgical procedures.
No takes yet. Share an insight, caveat, or question.
Mousavi et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: